Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04463771 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
A Phase 2 study of Endometrial Cancer, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT04463771: Active Phase 2 study of Endometrial Cancer, sponsored by Incyte Corporation.
NCT04463771 is a Phase 2 study of Endometrial Cancer that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 206 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04463771, a Phase 2 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.
Primary Outcome
Defined as the proportion of participants having a CR or PR according to RECIST v1.1, as assessed by Independent Central Review committee
Conditions Studied
Interventions
- DRUG INCAGN02385
- DRUG INCAGN02390
- DRUG retifanlimab
- DRUG epacadostat
- DRUG pemigatinib
Study Locations (20)
Florida
- Broward Health Medical Center - Fort Lauderdale
- Miami Cancer Institute - Miami
- Mount Sinai Medical Center Comprehensive Cancer Center - Miami Beach
- Advent Health Medical Group-Orlando 2501 - Orlando
- H. Lee Moffitt Cancer Center and Research Institute Hospital - Tampa
Arizona
- Honorhealth - Phoenix
- Arizona Oncology Associates - Tucson
California
- UCLA Medical Hematology & Oncology - Los Angeles
- Olive View Med Ctr - Sylmar
Missouri
- Midwest Cancer Care - Kansas City
- Washington University - St Louis
Alaska
- Alaska Womens Cancer Care Akwcc - Anchorage
Georgia
- Georgia Cancer Center - Augusta
Michigan
- Barbara Ann Karmanos Cancer Hospital - Detroit
Minnesota
- Minnesota Oncology-Maplewood - Coon Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2021-01-26 |
| Est. Completion | 2026-07-10 |
| Phase | Phase 2 |
What the registry record for NCT04463771 still lists
NCT04463771 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 5 interventions - of which INCAGN02385 is the first listed.
NCT04463771 names 20 study sites across 13 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04463771 about?
NCT04463771 is a clinical study titled "Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.". This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immun...
What is the current status of trial NCT04463771?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2021-01-26. Estimated completion is 2026-07-10.
What conditions does trial NCT04463771 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT04463771?
The interventions under investigation include: INCAGN02385 (DRUG), INCAGN02390 (DRUG), retifanlimab (DRUG), epacadostat (DRUG), pemigatinib (DRUG).
Who is sponsoring clinical trial NCT04463771?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04463771 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04463771's enrollment target sits among peer trials
206 65th of 181 higher than 117 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI